Anx-A1 and T cells in arthritis. (A) Paw volume and clinical score of DBA mice treated with PBS (100 μL) or hrAnx-A1 (1 μg subcutaneously twice a day) for 12 days during the immunization phase of the CIA model. Synchronization of disease onset was obtained by boosting with collagen on day 21, with clinical signs being evident from day 22 (day 1 of the onset of the diseases). Values are the mean ± SE of 6 to 8 mice. Groups were compared using the Mann-Whitney test. *P < .01. (B) Analysis of Anx-A1 expression in CD4⁺ cells of healthy control volunteers (HC) or patients with rheumatoid arthritis (RA). The median values are indicated by horizontal lines and P values of the Mann-Whitney test are shown. *P < .01. (C) Western blot analysis of Anx-A1 and β-actin levels in CD4⁺ cells of healthy control volunteers (HC) or patients with rheumatoid arthritis (RA). Results are representative of 5 different HCs or patients with RA. The bars represent the mean ratio ± SE of the optical density (OD) of Anx-A1 and β-actin bands from 5 different individuals. **P < .01.